April 24, 2018 / 8:05 AM / 3 months ago

BRIEF-Hikma Signs Licensing Agreement With Rovi For Enoxaparin Biosimilar

April 24 (Reuters) - Hikma Pharmaceuticals Plc:

* HIKMA EXPANDS LICENSING AGREEMENT WITH ROVI

* SIGNED A LICENSING AGREEMENT WITH LABORATORIOS FARMACEÚTICOS ROVI SA FOR THEIR ENOXAPARIN BIOSIMILAR

* UNDER TERMS OF AGREEMENT, HIKMA HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET ENOXAPARIN ACROSS ITS MENA MARKETS. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below